findmyKOL

Gary Hunninghake, MD

Enriched profile

Professor of Medicine · Brigham and Women's Hospital

ORCIDNPI
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyPulmonary DiseaseFocusInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2006–2026

Gary Hunninghake is Professor of Medicine at Brigham and Women's Hospital. OpenAlex indexes 221 publications with 15,053 citations (h-index 61); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Gary Hunninghake, MD, is Professor of Medicine at Brigham and Women's Hospital. The public record shows 221 publications with 15,053 citations (h-index 61), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Medical Imaging and Pathology Studies. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 4 companies, 5 NIH-funded awards (2006–2026).

  • Most recent indexed publication: 2026 · American journal of respiratory and critical care medicine
  • Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Idiopathic Pulmonary Fibrosis1 trialHypertension1 trialPulmonary HypertensionAsthmaCOPD

Research focus

OpenAlex concept fingerprint
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchMedical Imaging and Pathology StudiesAsthma and respiratory diseasesPulmonary Hypertension Research and Treatments

Drugs & molecules

across trials, industry payments and publications
Ofevgeneric · NintedanibClinical trialsIndustry payments16PublicationsTyvasogeneric · TreprostinilClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Boehringer Ingelheim International GmbHClinical trialsIndustry payments15Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trialsIndustry payments5Chugai Pharmaceutical Co., Ltd.Clinical trialsIndustry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
221publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

15,053citations

Total citations across indexed works.

61h-index

Hirsch index (OpenAlex). i10-index 125.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
4companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
5NIH grants · 2006–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    76.9%
    Kinase inhibitor53.1%
    Ofev100%
    Part D15 patients
    Pyridone23.8%
    Pirfenidone100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    23.1%
    Corticosteroid23.1%
    Prednisone100%
    Part D11 patients
Where care is delivered (Part B)68.5% facility · 31.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

5 NIH research awards on record, funded 20062026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Hiroto Hatabu92Rachel K. Putman78Iván O. Rosas70

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/gary-hunninghake-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Gary-Hunninghake

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/SchillerLab/status/1647890842353278977

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Awards & honors

honors on the public record
  • Elected member

    American Society for Clinical Investigation (ASCI)

    2015
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →the-asci.org

Secondary affiliations

appointments beyond the home institution
  • Professor of Medicine

    Harvard Medical School

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org

Media & interviews

press, podcasts and appearances
  • Guest

    "Approach to the Evaluation and Management of Interstitial Lung Abnormalities" episode, Out of the Blue: An AJRCCM Podcast (American Thoracic Society), with Anna Podolanczuk, hosted by Mohleen Kang

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →transistor.fm

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.